A Study to Compare the Lung Effect of Indacaterol and Tiotropium in Chronic Obstructive Pulmonary Disease (COPD) (INTENSITY)
This study has been completed.
Sponsor:
Novartis Pharmaceuticals
Information provided by:
Novartis
ClinicalTrials.gov Identifier:
NCT00900731
First received: May 12, 2009
Last updated: July 22, 2011
Last verified: July 2011
- Full Text View
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Purpose
This study compared the lung effects of indacaterol to those of tiotropium in patients with moderate to severe chronic obstructive pulmonary disease (COPD) over a 12 week period.
| Condition | Intervention | Phase |
|---|---|---|
|
Chronic Obstructive Pulmonary Disease |
Drug: Indacaterol 150 μg Drug: Tiotropium 18 μg Drug: Placebo to indacaterol Drug: Placebo to tiotropium |
Phase 3 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Intervention Model: Parallel Assignment Masking: Double Blind (Investigator, Outcomes Assessor) Primary Purpose: Treatment |
| Official Title: | A 12-week Treatment, Multicenter, Randomized, Parallel-group, Blinded, Double-dummy Study to Compare the Efficacy and Safety of Indacaterol (150 µg Once Daily [od]) Delivered Via a Single Dose Dry Powder Inhaler (SDDPI) With Tiotropium (18 µg od) Delivered Via a HandiHaler®, in Patients With Moderate-to-severe COPD |
Resource links provided by NLM:
Further study details as provided by Novartis:
Primary Outcome Measures:
- Trough Forced Expiratory Volume in 1 Second (FEV1) at End of Treatment (Week 12) [ Time Frame: End of treatment (Week 12) ] [ Designated as safety issue: No ]Spirometry was conducted according to internationally accepted standards. Trough FEV1 was defined as the average of the 23 hour 10 minute and 23 hour 45 minute post-dose FEV1 readings. Mixed model used baseline FEV1, FEV1 prior to and 10-15 minutes post inhalation of salbutamol/albuterol, FEV1 prior to and 1 hour post inhalation of ipratropium, and inhaled corticosteroid use at baseline as covariates.
Secondary Outcome Measures:
- Forced Expiratory Volume in 1 Second (FEV1) Standardized (With Respect to Time) Area Under the Curve (AUC) From 5 Minutes to 4 Hours Post-dose at the End of Treatment (Week 12) [ Time Frame: 5 minutes to 4 hours post-dose at the end of treatment (week 12) ] [ Designated as safety issue: No ]Spirometry was conducted according to internationally accepted standards. FEV1 was measured at 5 and 30 minutes; and 1, 2, and 4 hours post-dose on Week 12. Standardized FEV1 AUC (5 minutes-4 hour) post-dose at week 12 was calculated based on the trapezoidal rule, and was adjusted for the area per time unit by using the scheduled time of measurements for FEV1. Mixed model used baseline FEV1, FEV1 prior to and 10-15 minutes post inhalation of salbutamol/albuterol, FEV1 prior to and 1 hour post inhalation of ipratropium, and inhaled corticosteroid use at baseline as covariates.
- Transition Dyspnea Index (TDI) Focal Score After 12 Weeks of Treatment [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]TDI focal score is based on three domains: functional impairment, magnitude of task and magnitude of effort. Each domain is scored from -3 (major deterioration) to 3 (major improvement) to give an overall TDI focal score of -9 to 9 with a negative score indicating a deterioration from baseline. A 1 unit difference in the TDI focal score is clinically significant. Mixed model used baseline dyspnea index, FEV1 prior to and 10-15 minutes post inhalation of salbutamol/albuterol, FEV1 prior to and 1 hour post inhalation of ipratropium, and inhaled corticosteroid use at baseline as covariates.
- Quality of Life Assessment With St. George's Respiratory Questionnaire (SGRQ) Total Score After 12 Weeks of Treatment [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]SGRQ is a health related quality of life questionnaire consisting of 50 items in three domains: symptoms (frequency and severity), activity (that cause or are limited by breathlessness) and impacts (social functioning & psychological disturbances resulting from airway disease). The total score is 0 to 100 with a higher score indicating greater impairment of health status. Mixed model used baseline SGRQ, FEV1 prior to and 10-15 minutes post inhalation of salbutamol/albuterol, FEV1 prior to and 1 hour post inhalation of ipratropium, and inhaled corticosteroid use at baseline as covariates.
- Change From Baseline in the Mean Number of Puffs Per Day of Rescue Medication Over the Study Duration (From Day 1 to Week 12) [ Time Frame: Baseline, up to 12 weeks ] [ Designated as safety issue: No ]Participants recorded the number of puffs of rescue medication taken in the previous 12 hours each morning and evening in an electronic diary. The number of puffs per day over the 12 weeks of treatment was divided by the number of days to derive the mean number per day of puffs of rescue medication for each participant. Mixed model used baseline number of puffs per day of rescue medication, FEV1 prior to and 10-15 minutes post inhalation of salbutamol/albuterol, FEV1 prior to and 1 hour post inhalation of ipratropium, and inhaled corticosteroid use at baseline as covariates.
- Change From Baseline in the Mean Number Per Day of Daytime Puffs of Rescue Medication Over the Study Duration (From Day 1 to Week 12) [ Time Frame: Baseline, up to 12 weeks ] [ Designated as safety issue: No ]Participants recorded the number of puffs of rescue medication taken in the previous 12 hours each evening in an electronic diary. The number of daytime puffs per day over the 12 weeks of treatment was divided by the number of days to derive the mean number per day of daytime puffs of rescue medication for each participant. Mixed model used baseline number of daytime puffs per day of rescue medication, FEV1 prior to and 10-15 minutes post inhalation of salbutamol/albuterol, FEV1 prior to and 1 hour post inhalation of ipratropium, and inhaled corticosteroid use at baseline as covariates.
- Change From Baseline in the Mean Number Per Day of Nighttime Puffs of Rescue Medication Over the Study Duration (From Day 1 to Week 12) [ Time Frame: Baseline, up to 12 weeks ] [ Designated as safety issue: No ]Participants recorded the number of puffs of rescue medication taken in the previous 12 hours each morning in an electronic diary. The number of nighttime puffs per day over the 12 weeks of treatment was divided by the number of days to derive the mean number per day of nighttime puffs of rescue medication for each participant. Mixed model used baseline number of nighttime puffs per day of rescue medication, FEV1 prior to and 10-15 minutes post inhalation of salbutamol/albuterol, FEV1 prior to and 1 hour post inhalation of ipratropium, and inhaled corticosteroid use at baseline as covariates.
- Percentage of Days With no Rescue Medication Use During the 12 Weeks of Treatment [ Time Frame: Up to 12 weeks ] [ Designated as safety issue: No ]A day with no rescue medication was defined as any day in the diary that the participant used no puffs of rescue medication. The percentage of days with no rescue medication was calculated by dividing the number of days with no rescue medication over the 12 week treatment period by the number of evaluable days and multiplying by 100. Mixed model used baseline percentage of days with no rescue medication, FEV1 prior to and 10-15 minutes post inhalation of salbutamol/albuterol, FEV1 prior to and 1 hour post inhalation of ipratropium, and inhaled corticosteroid use at baseline as covariates.
| Enrollment: | 1598 |
| Study Start Date: | June 2009 |
| Study Completion Date: | March 2010 |
| Primary Completion Date: | March 2010 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: Indacaterol 150 µg
Participants received indacaterol 150 μg delivered via a single-dose dry-powder inhaler (SDDPI) plus placebo to tiotropium delivered via the manufacturer's proprietary inhalation device (HandiHaler®) once daily in the morning. Participants were permitted to take salbutamol/albuterol as a rescue medication.
|
Drug: Indacaterol 150 μg
Indacaterol 150 μg was provided in powder filled capsules with a single dose dry powder inhaler (SDDPI).
Drug: Placebo to tiotropium
Placebo to tiotropium was provided in powder filled capsules with the manufacturer's proprietary inhalation device (HandiHaler®).
|
|
Active Comparator: Tiotropium 18 µg
Participants received tiotropium 18 μg delivered via the manufacturer's proprietary inhalation device (HandiHaler®) plus placebo to indacaterol delivered via a single-dose dry-powder inhaler (SDDPI) once daily in the morning. Participants were permitted to take salbutamol/albuterol as a rescue medication.
|
Drug: Tiotropium 18 μg
Tiotropium 18 μg was provided in powder filled capsules with the manufacturer's proprietary inhalation device (HandiHaler®).
Drug: Placebo to indacaterol
Placebo to indacaterol was provided in powder filled capsules with a single dose dry powder inhaler (SDDPI).
|
Eligibility| Ages Eligible for Study: | 40 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Diagnosis of COPD (moderate-to-severe as classified by the Global Initiative for Chronic Obstructive Lung Disease (GOLD) Guidelines, 2007) and:
- a) Smoking history of at least 10 pack-years
- b) Post-bronchodilator forced expiratory volume in 1 second (FEV1) < 80% and ≥ 30% of the predicted normal value
- c) Post-bronchodilator FEV1/FVC (forced vital capacity) < 70%
Exclusion Criteria:
- Patients who have received systemic corticosteroids or antibiotics and/or was hospitalized for a COPD exacerbation in the 6 weeks prior to screening
- Patients who have had a respiratory tract infection within 6 weeks prior to screening
- Patients with concomitant pulmonary disease
- Patients with a history of asthma
- Patients with diabetes Type I or uncontrolled diabetes Type II
- Any patient with lung cancer or a history of lung cancer
- Patients with a history of certain cardiovascular comorbid conditions
Other protocol-defined inclusion/exclusion criteria applied to the study.
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00900731
Hide Study Locations
Hide Study LocationsLocations
| United States, Alabama | |
| Novartis Investigative Site | |
| Birmingham, Alabama, United States, 35209 | |
| Novartis Investigator Site | |
| Jasper, Alabama, United States, 35501 | |
| United States, Arizona | |
| Novartis Investigative Site | |
| Phoenix, Arizona, United States, 85050 | |
| Novartis Investigative Site | |
| Tucson, Arizona, United States, 85723 | |
| United States, California | |
| Novartis Investigator Site | |
| Anaheim, California, United States, 92801 | |
| Novartis Investigator Site | |
| Stockton, California, United States, 95207 | |
| Novartis Investigator Site | |
| Walnut Creek, California, United States, 94598 | |
| United States, Colorado | |
| Novartis Investigator Site | |
| Fort Collins, Colorado, United States, 80528 | |
| Novartis Investigator Site | |
| Wheat Ridge, Colorado, United States, 80033 | |
| United States, Florida | |
| Novartis Investigative Site | |
| South Miami, Florida, United States, 33143 | |
| United States, Illinois | |
| Novartis Investigator Site | |
| Normal, Illinois, United States, 61761 | |
| United States, Indiana | |
| Novartis Investigative Site | |
| Evansville, Indiana, United States, 47710 | |
| United States, Kansas | |
| Novartis Investigative Site | |
| Topeka, Kansas, United States, 66606 | |
| United States, Louisiana | |
| Novartis Investigative Site | |
| Lafayette, Louisiana, United States, 70503 | |
| United States, Missouri | |
| Novartis Investigative Center | |
| St Charles, Missouri, United States, 63301 | |
| Novartis Investigative Site | |
| St Louis, Missouri, United States, 63141 | |
| United States, Nebraska | |
| Novartis Investigative Site | |
| Lincoln, Nebraska, United States, 68510 | |
| United States, Nevada | |
| Novartis Investigative Site | |
| Henderson, Nevada, United States, 89014 | |
| United States, New York | |
| Novartis Investigative Site | |
| Albany, New York, United States, 12205 | |
| Novartis Investigative Site | |
| Larchmont, New York, United States, 10538 | |
| Novartis Investigative Site | |
| New York, New York, United States, 10016 | |
| United States, North Carolina | |
| Novartis Investigative Site | |
| Charlotte, North Carolina, United States, 28207 | |
| United States, Ohio | |
| Novartis Investigative Site | |
| Columbus, Ohio, United States, 43214 | |
| United States, Texas | |
| Novartis Investigative Site | |
| San Antonio, Texas, United States, 78229 | |
| United States, Virginia | |
| Novartis Investigative Site | |
| Richmond, Virginia, United States, 23229 | |
| Austria | |
| Novartis Investigator Site | |
| Feldbach, Austria | |
| Novartis Investigator Site | |
| Gänserndorf, Austria | |
| Novartis Investigator Site | |
| Hallein, Austria | |
| Belgium | |
| Novartis Investigator Site | |
| Bruxelles, Belgium | |
| Novartis Investigator Site | |
| Gilly, Belgium | |
| Novartis Investigator Site | |
| Jambes, Belgium | |
| Novartis Investigator Site | |
| Jette, Belgium | |
| Novartis Investigator Site | |
| Liège, Belgium | |
| Novartis Investigator Site | |
| Montigny-le-tilleul, Belgium | |
| Novartis Investigator Site | |
| Oostende, Belgium | |
| Novartis Investigator Site | |
| Saint Vith, Belgium | |
| Novartis Investigator Site | |
| Yvoir, Belgium | |
| Canada | |
| Novartis Investigator Site | |
| Calgary, Canada | |
| Novartis Investigative Site | |
| Mississauga, Canada | |
| Novartis Investigative Site | |
| Moncton, Canada | |
| Novartis Investigative Site | |
| New Market, Canada | |
| Novartis Investigative SIte | |
| Quebec, Canada | |
| Novartis Investigative Site | |
| St-Romuald, Canada | |
| Novartis Investigative Site | |
| Sudbury, Canada | |
| Colombia | |
| Novartis Investigator Site | |
| Barranquilla, Colombia | |
| Novartis Investigator Site | |
| Bogota, Colombia | |
| Novartis Investigator Site | |
| Medellin, Colombia | |
| Denmark | |
| Novartis Investigator Site | |
| Aalborg, Denmark | |
| Novartis Investigator Site | |
| Frederiksberg, Denmark | |
| Novartis Investigator Site | |
| Næstved, Denmark | |
| Novartis Investigator Site | |
| Roskilde, Denmark | |
| Novartis Investigator Site | |
| Sønderborg, Denmark | |
| Novartis Investigator Site | |
| Vaerlose, Denmark | |
| Novartis Investigator Site | |
| Viborg, Denmark | |
| Finland | |
| Novartis Investigator Site | |
| Helsinki, Finland | |
| Novartis Investigator Site | |
| Jyväskylä, Finland | |
| Novartis Investigator Site | |
| Lahti, Finland | |
| Novartis Investigator Site | |
| OYS, Finland | |
| Novartis Investigator Site | |
| Pori, Finland | |
| Novartis Investigator Site | |
| Turku, Finland | |
| France | |
| Novartis Investigative Site | |
| Ambroise, France | |
| Novartis Investigative Site | |
| Antibes, France | |
| Novartis Investigator Site | |
| Beuvry, France | |
| Novartis Investigator Site | |
| Ferolles-Attily, France | |
| Novartis Investigative Site | |
| Montpellier, France | |
| Novartis Investigator Site | |
| Nantes, France | |
| Novartis Investigative Site | |
| Nice, France | |
| Novartis Investigative Site | |
| Nimes, France | |
| Novartis Investigative Site | |
| Paris, France | |
| Novartis Investigator Site | |
| Paris, France | |
| Novartis Investigative Site | |
| Pessac, France | |
| Novartis Investigator Site | |
| Pierre Benite, France | |
| Novartis Investigative Site | |
| Suresnes, France | |
| Novartis Investigator Site | |
| Vandoeuvre Les Nancys, France | |
| Germany | |
| Novartis Investigator Site | |
| Bergisch Gladbach, Germany | |
| Novartis Investigator Site | |
| Berlin, Germany | |
| Novartis Investigator Site | |
| Bochum, Germany | |
| Novartis Investigator Site | |
| Bonn, Germany | |
| Novartis Investigator Site | |
| Buchholz, Germany | |
| Novartis Investigator Site | |
| Coburg, Germany | |
| Novartis Investigator Site | |
| Dueren, Germany | |
| Novartis Investigator Site | |
| Eggenfelden, Germany | |
| Novartis Investigator Site | |
| Eschwege, Germany | |
| Novartis Investigator Site | |
| Euskirchen, Germany | |
| Novartis Investigator Site | |
| Freudenberg, Germany | |
| Novartis Investigator Site | |
| Fürth, Germany | |
| Novartis Investigator Site | |
| Gelsenkirchen, Germany | |
| Novartis Investigator Site | |
| Gummersbach, Germany | |
| Novartis Investigator Site | |
| Hagen, Germany | |
| Novartis Investigator Site | |
| Halle, Germany | |
| Novartis Investigator Site | |
| Hamburg, Germany | |
| Novartis Investigator Site | |
| Hannover, Germany | |
| Novartis Investigator Site | |
| Hoyerswerda, Germany | |
| Novartis Investigator Site | |
| Kassel, Germany | |
| Novartis Investigative Site | |
| Landsberg, Germany | |
| Novartis Investigator Site | |
| Leipzig, Germany | |
| Novartis Investigator Site | |
| Mainz, Germany | |
| Novartis Investigator Site | |
| Munich, Germany | |
| Novartis Investigator Site | |
| Oranienburg, Germany | |
| Novartis Investigator Site | |
| Radebeul, Germany | |
| Novartis Investigator Site | |
| Ratingen, Germany | |
| Novartis Investigator Site | |
| Ruhmannsfelden, Germany | |
| Novartis Investigator Site | |
| Rüsselsheim, Germany | |
| Novartis Investigator Site | |
| Solingen, Germany | |
| Novartis Investigator Site | |
| Stockach, Germany | |
| Novartis Investigator Site | |
| Teterow, Germany | |
| Novartis Investigator Site | |
| Vilshofen, Germany | |
| Novartis Investigator Site | |
| Wallerfing, Germany | |
| Novartis Investigator Site | |
| Wissen, Germany | |
| Greece | |
| Novartis Investigator Site | |
| Athens, Greece | |
| Hungary | |
| Novartis Investigative Site | |
| Budapest, Hungary | |
| Novartis Investigator Site | |
| Budapest, Hungary | |
| Novartis Investigator Site | |
| Debrecen, Hungary | |
| Novartis Investigative Site | |
| Farkasgyepu, Hungary | |
| Novartis Investigative Site | |
| Godollo, Hungary | |
| Novartis Investigator Site | |
| Szolnok, Hungary | |
| Israel | |
| Novartis Investigator Site | |
| Haifa, Israel | |
| Novartis Investigator Site | |
| Petach-Tikva, Israel | |
| Italy | |
| Novartis Investigator Site | |
| Ancona, Italy | |
| Novartis Investigator Site | |
| Foggia, Italy | |
| Novartis Investigator Site | |
| Milano, Italy | |
| Novartis Investigative Site | |
| Milano, Italy | |
| Novartis Investigator Site | |
| Pavia, Italy | |
| Novartis Investigative Site | |
| Pavia, Italy | |
| Novartis Investigator Site | |
| Pisa, Italy | |
| Novartis Investigative Site | |
| Pisa, Italy | |
| Mexico | |
| Novartis Investigative Site | |
| Huxquilucan, Mexico | |
| Novartis Investigator Site | |
| Mexico City, Mexico | |
| Novartis Investigative Site | |
| San Luis Potosi, Mexico | |
| Norway | |
| Novartis Investigator Site | |
| Drammen, Norway | |
| Novartis Investigator Site | |
| Follebu, Norway | |
| Novartis Investigator Site | |
| Kongsberg, Norway | |
| Novartis Investigative Site | |
| Kongsberg, Norway | |
| Novartis Investigator Site | |
| Kongsvinger, Norway | |
| Novartis Investigator Site | |
| Lierskogen, Norway | |
| Novartis Investigative Site | |
| Oslo, Norway | |
| Novartis Investigator Site | |
| Oslo, Norway | |
| Novartis Investigator Site | |
| Sandvika, Norway | |
| Novartis Investigative Site | |
| Skedsmokorset, Norway | |
| Novartis Investigator Site | |
| Stavanger, Norway | |
| Novartis Investigator Site | |
| Trondheim, Norway | |
| Novartis Investigative Site | |
| Trondheim, Norway | |
| Novartis Investigator Site | |
| Ålesund, Norway | |
| Novartis Investigative Site | |
| Ålesund, Norway | |
| Poland | |
| Novartis Investigator Site | |
| Gdansk, Poland | |
| Novartis Investigator Site | |
| Katowice, Poland | |
| Novartis Investigator Site | |
| Krakow, Poland | |
| Novartis Investigative Site | |
| Krakow, Poland | |
| Novartis Investigator Site | |
| Piekary Slaskie, Poland | |
| Novartis Investigator Site | |
| Warszawa, Poland | |
| Novartis Investigator Site | |
| Wroclaw, Poland | |
| Russian Federation | |
| Novartis Investigator Site | |
| Barnaul, Russian Federation | |
| Novartis Investigator Site | |
| Ekaterinburg, Russian Federation | |
| Novartis Investigator Site | |
| Kazan, Russian Federation | |
| Novartis Investigator Site | |
| Novosibirsk, Russian Federation | |
| Novartis Investigator Site | |
| Petrozavodsk, Russian Federation | |
| Novartis Investigator Site | |
| Ryazan, Russian Federation | |
| Novartis Investigator Site | |
| Saint-Petersburg, Russian Federation | |
| Novartis Investigative Site | |
| Saint-Petersburg, Russian Federation | |
| Novartis Investigator Site | |
| Samara, Russian Federation | |
| Slovakia | |
| Novartis Investigator Site | |
| Bratislava, Slovakia | |
| Novartis Investigative Site | |
| Kosice, Slovakia | |
| Novartis Investigator Site | |
| Kosice, Slovakia | |
| Novartis Investigator Site | |
| Kralovsky Chlmec, Slovakia | |
| Novartis Investigator Site | |
| Nitra, Slovakia | |
| Novartis Investigative Site | |
| Presov, Slovakia | |
| Novartis Investigator Site | |
| Zvolen, Slovakia | |
| Spain | |
| Novartis Investigative Site | |
| Alcorcón, Spain | |
| Novartis Investigator Site | |
| Alicante, Spain | |
| Novartis Investigator Site | |
| Badalona, Spain | |
| Novartis Investigative Site | |
| Barcelona, Spain | |
| Novartis Investigative Site | |
| Begonte, Spain | |
| Novartis Investigator Site | |
| Burgos, Spain | |
| Novartis Investigator Site | |
| Caceres, Spain | |
| Novartis Investigator Site | |
| Canet de Mar, Spain | |
| Novartis Investigative Site | |
| Fuenlabrada, Spain | |
| Novartis Investigative Site | |
| Girona, Spain | |
| Novartis Investigative Site | |
| Madrid, Spain | |
| Novartis Investigator Site | |
| Mataro, Spain | |
| Novartis Investigator Site | |
| Plasencia, Spain | |
| Novartis Investigative Site | |
| Ponferrada, Spain | |
| Novartis Investigative Site | |
| Pontevedra, Spain | |
| Novartis Investigator Site | |
| Prat de Llobregat, Spain | |
| Novartis Investigative Site | |
| Santander, Spain | |
| Novartis Investigative Site | |
| Valencia, Spain | |
| Novartis Investigative Site | |
| Vila-real, Spain | |
| Switzerland | |
| Novartis Investigator Site | |
| Basel, Switzerland | |
| Novartis Investigator Site | |
| Bellinzona, Switzerland | |
| Novartis Investigator Site | |
| Lugano, Switzerland | |
| Novartis Investigator Site | |
| Muenchenstein, Switzerland | |
| Novartis Investigative Site | |
| Zuerich, Switzerland | |
| Turkey | |
| Novartis Investigator Site | |
| Altunizade, Turkey | |
| Novartis Investigator Site | |
| Ankara, Turkey | |
| Novartis Investigative Site | |
| Aydin, Turkey | |
| Novartis Investigator Site | |
| Büyükçekmece / Ýstanbul, Turkey | |
| Novartis Investigative Site | |
| Fatih / Istanbul, Turkey | |
| Novartis Investigator Site | |
| Istanbul, Turkey | |
| Novartis Investigator Site | |
| Kahramanmaras, Turkey | |
| Novartis Investigative Site | |
| Mecidiyekoy/Istanbul, Turkey | |
| Novartis Investigative Site | |
| Mersin, Turkey | |
| Novartis Investigative Site | |
| Soke / Aydin, Turkey | |
| Novartis Investigative Site | |
| Yenisehir/Izmir, Turkey | |
| United Kingdom | |
| Novartis Investigator Site | |
| Ash Vale, United Kingdom | |
| Novartis Investigator Site | |
| Ashford, United Kingdom | |
| Novartis Investigator Site | |
| Bolton, United Kingdom | |
| Novartis Investigator Site | |
| Boscastle, United Kingdom | |
| Novartis Investigator Site | |
| Bradford, United Kingdom | |
| Novartis Investigator Site | |
| Chertsey, United Kingdom | |
| Novartis Investigator Site | |
| East Horsley, United Kingdom | |
| Novartis Investigator Site | |
| Newcastle-upon-Tyne, United Kingdom | |
| Novartis Investigator Site | |
| Plymouth, United Kingdom | |
| Novartis Investigator Site | |
| Watford, United Kingdom | |
Sponsors and Collaborators
Novartis Pharmaceuticals
Investigators
| Study Director: | Novartis Pharmaceuticals | Novartis Pharmaceuticals |
More Information
No publications provided by Novartis
Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | External Affairs, Novartis Pharmaceuticals |
| ClinicalTrials.gov Identifier: | NCT00900731 History of Changes |
| Other Study ID Numbers: | CQAB149B2350 |
| Study First Received: | May 12, 2009 |
| Results First Received: | July 22, 2011 |
| Last Updated: | July 22, 2011 |
| Health Authority: | United States: Food and Drug Administration Slovakia: State Institute for Drug Control Belgium: Federal Agency for Medicinal Products and Health Products Norway: Norwegian Medicines Agency Switzerland: Ethikkommission United Kingdom: Medicines and Healthcare Products Regulatory Agency Austria: Federal Office for Safety in Health Care Colombia: INVIMA Instituto Nacional de Vigilancia de Medicamentos y Alimentos France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis) Germany: Federal Institute for Drugs and Medical Devices Greece: National Organization of Medicines Hungary: National Institute of Pharmacy Israel: Ethics Commission Mexico: Ministry of Health Poland: Office for Registration of Medicinal Products, Medical Devices and Biocidal Products Russia: Ministry of Health of the Russian Federation Canada: Health Canada |
Keywords provided by Novartis:
|
COPD indacaterol beta 2 agonist tiotropium |
Additional relevant MeSH terms:
|
Lung Diseases Respiration Disorders Pulmonary Disease, Chronic Obstructive Lung Diseases, Obstructive Respiratory Tract Diseases Tiotropium Parasympatholytics Autonomic Agents Peripheral Nervous System Agents Physiological Effects of Drugs |
Pharmacologic Actions Cholinergic Antagonists Cholinergic Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Bronchodilator Agents Anti-Asthmatic Agents Respiratory System Agents Therapeutic Uses |
ClinicalTrials.gov processed this record on May 19, 2013